Skip to main content

Table 2 Patient vaccination and outcome

From: HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial

ID Vaccination Clinical outcome Radiology results
  (n) injections Additional treatment Chemotherapeutic drug Interval 1st Vac-Chemo (months) Status Survival (months) Pre-post scans interval (months) Baseline sum LD (mm) Post vaccination sum LD (mm) Target lesions Non-target lesions (RECIST)
1 4     died 9 8.1 120 161 PD PD
2 3 RT    died 21 6.4 52 70 PD PD
3 3 CH + RT Cisplatin/Topotecan 1.9 died 19 2.4 132 138 SD PD
4 3     died 8 4.8 149 189 PD PD
5 2     died 6 1.8 68 89 PD PD
6 2     died 4      
7 2 CH Carboplatin/Gemcitabin 1.0 died 13 6.2 NE NE NE NE
8 4 CHRT/SUR Carboplatin/Taxol 4.2 died 26 5.5 31 61 PD PD
9 4 CH Cisplatin/Topotecan 4.0 died 26 3.9 67 67 SD PD
10 4     died 25 4.7 68 88 PD PD
11 4     died 7      
12 3     died 15      
13 4     died 5 3.6 87 80 SD PD
14 4     died 7 1.3 112 151 PD PD
15 3     died 8 3.5 0 0   PD
16 2     died 7      
17 4 CH Cisplatin/Topotecan 2.1 UK 20      
18 0     died 4      
19 4     died 15      
20 4     died 37      
21 4     died 12 4.7 63 79 PD PD
  1. CH, chemotherapy; CHRT, chemoradiation; LD, longest diameter; NE, not evaluable; PD, progressive disease; RT, radiotherapy; SD, stable disease, SUR, surgery. The interval between the 1st vaccination and the chemotherapy after the vaccinations (1st Vac-Chemo) was calculated by using the date of first vaccination and the starting date of the given chemotherapy during/after the vaccinations as reference points.